GnRH Agonist Regulates Glucagon Release in In-R1-G9 Cells Through ERK MAPK Pathway

TAO Xiao-qian,SHI Shan-shan,ZHANG Yan-mei,LIU Hai-yan,LU Kun-gang,HAN Xue-feng,YAO Bing
DOI: https://doi.org/10.13602/j.cnki.jcls.2010.01.006
2010-01-01
Abstract:Objective To investigate whether the effect of GnRH agonist(GnRHa) on glucagon release in In-R1-G9 cells is relevant to mitogen-activated protein kinases(MAPK) signaling pathway.Methods The In-R1-G9 cells were serum-starved for 24 h before GnRHa treatment,and then 100 nmol/L GnRHa stimulated the cells for 0,5,10,20,30,60,90 min,respectively.Phosphorylated extracellular signal-regulated kinase(p-ERK),total ERK(T-ERK),phosphorylated p38,and β-actin were detected by Western blotting.After In-R1-G9 cells were treated with ERK inhibitor PD98059(50 μmol/L),glucagon was measured by radioimmunoassay.Results The level of p-ERK increased significantly at 20 min(P0.05) after In-R1-G9 cells were stimulated by GnRHa and the peak of p-ERK level occurred at 30 min(P0.01).p-ERK in the cells treated by GnRHa increased by 169% compared with that in the control group.Then it decreased to normal level at 90 min.However,the level of P-p38 had no significant change at each time point compared with that of the control group.There was significant disparity when PD98059 group was compared with DMSO group(P0.05) and GnRHa+PD98059 group was compared with GnRHa group(P0.01).Conclusions GnRHa regulates glucagon release in In-R1-G9 cells through ERK1/2 MAPK pathway rather than p38 MAPK pathway.
What problem does this paper attempt to address?